Popular weight-loss drug Wegovy goes on sale in China
Published On Nov 18, 2024, 11:34 PM
Novo Nordisk has launched its weight-loss drug Wegovy in China after receiving approval from local health authorities. This move provides access to an estimated 180 million people suffering from obesity in the country and intensifies competition with Eli Lilly's weight-loss treatment, which has not yet rolled out. The price of Wegovy in China is significantly lower than in the U.S., although patients will have to pay out-of-pocket as it is not yet covered by national healthcare insurance. Research indicates that patients can expect to lose over 10% of their body weight with Wegovy, although some may experience side effects and potential weight regain after cessation of treatment. The launch positions Novo Nordisk favorably in a major pharmaceutical market as the drug's popularity continues to grow globally, benefiting from high demand and celebrity endorsements.